5-氯-1-(呋喃-2-基甲氧基甲基)嘧啶-2-酮 | 88045-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氯-1-(呋喃-2-基甲氧基甲基)嘧啶-2-酮
• 英文名称: 5-chloro-1-(2-furfuryloxy)methyl-2(1H)-pyrimidinone
• 英文别名: 5-Chloro-1-{[(furan-2-yl)methoxy]methyl}pyrimidin-2(1H)-one；5-chloro-1-(furan-2-ylmethoxymethyl)pyrimidin-2-one
• CAS: 88045-86-7
• 化学式: C₁₀H₉ClN₂O₃
• 分子量: 240.646
• InChiKey: RCJPQNPONAAIMA-UHFFFAOYSA-N

物化性质

• 沸点：
  330.7±52.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-羟基-5-氯嘧啶 、 chloromethyl 2-furfuryl ether 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以54%的产率得到5-氯-1-(呋喃-2-基甲氧基甲基)嘧啶-2-酮
  参考文献：
  名称：

  Pyrimidinones as reversible metaphase arresting agents

  摘要：

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.

  DOI：

  10.1016/0223-5234(93)90014-6

文献信息

• Substituted pyrimidin-2-ones and the salts thereof
  申请人：NYCOMED AS

  公开号：EP0087326A1

  公开（公告）日：1983-08-31

  ompounds of the general formula :- wherein X represents halogen or trifluoromethyl; R1 and R2, independently represent hydrogen or lower alkyl; R3, R4 and R5, which may be the same or different, each represent hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkenoyl, C7-16 aralkyl or C6-10 aryl or a 5-9 membered unsaturated or aromatic heterocyclic ring: one or both of R4 and R5 may also represent aroyl groups; Z represents an oxygen atom or a sulfur atom or oxide thereof or a group NR6 (wherein R6 is as defined for R hereinafter or represents the group COR7 in which R7 represents hydrogen or optionally substituted aryl, heterocyclic, aralkyl, lower alkyl or lower alkoxy group; and R represents a C6-10 carbocyclic aromatic group or a heterocyclic group containing a 5-9 membered unsaturated or aromatic heterocyclic ring which ring contains one or more heteroatoms selected from O. N and S and optionally carries a fused ring which carbocyclic or heterocyclic group may carry one or more C1-4 alkyl or phenyl groups said groups being optionally substituted; and where acid or basic groups are present, the salts thereof are useful in combating abnormal cell proliferation. The compounds of the invention are prepared by inter alia alkylation, ring closure and oxidation.

  通式如下的化合物 其中 X 代表卤素或三氟甲基； R1 和 R2 各自代表氢或低级烷基； R3、R4 和 R5（可以相同或不同）各自代表氢、低级烷基、低级烯基、低级炔基、低级烷酰基、低级烯酰基、C7-16 芳基或 C6-10 芳基或 5-9 分子不饱和或芳香杂环：R4 和 R5 中的一个或两个还可以代表芳基； Z 代表氧原子或硫原子或其氧化物或基团 NR6（其中 R6 与下文中 R 的定义相同）或代表基团 COR7（其中 R7 代表氢或任选取代的芳基、杂环基、芳烷基、低级烷基或低级烷氧基）；以及 R代表C6-10碳环芳香基团或含有5-9个成员的不饱和或芳香杂环的杂环基团，该环含有一个或多个选自O、N和S的杂原子，并可选择带有一个融合环，该碳环或杂环基团可带有一个或多个C1-4烷基或苯基，所述基团可选择被取代；当存在酸性或碱性基团时，其盐类可用于对抗异常细胞增殖。 本发明的化合物可通过烷基化、闭环和氧化等方法制备。
• US4539324A
  申请人：——

  公开号：US4539324A

  公开（公告）日：1985-09-03
• Pyrimidinones as reversible metaphase arresting agents
  作者：T Benneche、P Strande、R Oftebro、K Undheim

  DOI：10.1016/0223-5234(93)90014-6

  日期：1993.1

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.